Preview

Качественная клиническая практика

Расширенный поиск

Линезолид - первый препарат нового класса антибактериальных средств оксазолидинонов

Полный текст:

Аннотация

В статье описан новый класс антибактериальных препаратов - оксазолидинонов, среди который первый - линезолид - эффективный препарат для лечения MRSA-инфекции.

Об авторах

О. В. Ефременкова
ГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва
Россия

кафедра клинической фармакологии



Ю. Б. Белоусов
ГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва
д.м.н., проф., зав. кафедрой клинической фармакологии


Список литературы

1. Norrby R. Linezolid - a review of the first oxazolidinone. Exp Opin Pharmacother 2001; 2(2): 93-302.

2. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358:1975-82.

3. Brickner SJ, Hutchinson DK, Barbachyn MR et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment

4. of multi-drug resistant Gram-positive bacterial infections. J Med Chem 1996; 39:673-679.

5. Shinabarger DL, Marotti KR, Murray RW et al. Mechanism of action of the oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents

6. Chemother 1997; 41:2132-2136.

7. Jones RN, Johson DM, Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766 two novel fluorinated oxazolidinones. Antimicrob Agents

8. Chemother 1996; 40:720-726.

9. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel îxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-845.

10. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinones U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative

11. Staphylococcus species. Antimicrob Agents Chemother 1997; 41:465-467.

12. Goldtsein EJC, Citron DM, Meeriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft

13. tissue bite infections in humans. Antimicrob Agents Chemother 1999; 43:1469-1474.

14. Wise R, Andrews JM, Boswell FJ et al. The in-vitro activity of linezolid and tentative breakpoints. J Antimicrob Chemother 1998; 42:721-728.

15. Mason EO, Jr., Lamberth LB, Kaplan SL. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains

16. of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40:1039-1040.

17. Eliopulos GM, Wennersten CB, Gold HS et al. In vitro activities of new oxazolidinones antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996; 40:1745-1747.

18. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents

19. Chemother 1996; 40:799-801.

20. Rybak MJ, Cappelletty DM, Moldovan T et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid

21. (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents

22. Chemother 1998; 42:721-724.

23. Noskin GA, Siddiqui F, Stosor V et al. In vitro activities of linezolid against important Gram-positive bacterial patogens including vancomycin-resistant enterococci.

24. Antimicrob Agents Chemother 1999; 43: 2059-2062.

25. Rybak MJ,,Hershberger E, Moldovan T et al. In vitro activities of daptomycin, vancomycin, linezolid and quinopristin-dalfopristin against staphylococci and enterococci,

26. including vancomycin-intermediate and strains. Antimicrob Agents Chemother 2000; 44:1062-1066.

27. Schülin T, Wenersten CB, Ferraro MJ et al. Susceptibilities of Legionella spp. to newer antimicrobial in vitro. Antimicrob Agents Chemother 1998; 42:1520-1523.

28. Marchese A, Schito GC. The oxazolidinones as a new family of antimicrobial agent. Clin Microbiol Infect 2001; 7 (Suppl. 4): 66-74.

29. Murray RW, Schaadt RD, Zurenko GE. Ribosomes from an oxazolidinone- resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free

30. transcription-translation assay. Antimicrob Agents Chemother 1998; 42: 947-950.

31. Clemett D, Markham A. Linezolid. Drugs 2000; 59(4):815-827.

32. Cynamon MH, Klemens SP, Sharpe CA et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents

33. Chemother 1999; 43:1189-1191.

34. Ford CW, Hamel JC, Wilson DM et al. In vivo activities of U-100592 and U-100766, novel îxazolidinone antimicrobial agents, against experimental bacterial infections.

35. Antimicrob Agents Chemother 2000; 44: 1508-1613.

36. Pelton SI, Figuera M, Albut R et al. Efficacy of linezolid in experimental otitis media. Antimicrob Agents Chemother 2000; 44: 654-657.

37. Diekema DJ, Jones RN. Oxazolidinones: a review. Drugs 2000; 59: 7-16.

38. Bouza E, Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect 2001; 7 (Suppl. 4): 75-82.

39. Herndershof PE, Jungbluth GL, Cammarata SK et al. Pharmacokinetics of linezolid in patients with liver disease. J Antimicrob Chemother 1999; 44(Suppl. A):55. Abstract.

40. Conte JE Jr, Golden JA, Kipps JE et al. Intrapulmonary pharmacokinetics of linezolid. The 40th ICAAC. Toronto, Canada 2000. Abstract No. 659.

41. Molinari M, Mangano R, Gough M et al. Linezolid in the treatment of streptococcal skin and soft tissue infections: combined results from three Phase III trials. Clin Microbiol

42. Infect 2000; 6(Suppl. 1):64. Abstract.

43. Regazzi M.B. et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002; 46: 936-937.

44. Duvall S, Bruss J, Todd W et al. Linezolid in the treatment of staphylococcal skin and soft tissue infections: combined results from three Phase III trials. Clin Microbiol

45. Infect 2000; 6(Suppl. 1):64. Abstract.

46. Cammarata SK, San Pedro GS, Timm JA et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community

47. acquired pneumonia:European results. Clin Microbiol Infect 2000; 6(Suppl. 1):136. Abstract.

48. Cammarata SK, Standford H, Todd WM et al. Linezolid eradicates common pathogens in community-acquired pneumonia. Clin Microbiol Infect 2000; 6(Suppl. 1):136. Abstract.

49. Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue

50. infections. Antimicrob Agents Chemother 2000; 44: 3408-3413.

51. Rubinstein E, Cammarata SK, Oliphant T et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia:

52. a randomized, double-blind multicenter study. Clin Infect Dis 2001; 32: 402-412.

53. Cammarata SK, Le V, Oliphant TH et al. Incidence of Clostridium difficile related complications during clinical trials of linezolid, an oxazolidinone. The 40th ICAAC. Toronto,

54. Canada 2000. Abstract 2132.


Для цитирования:


Ефременкова О.В., Белоусов Ю.Б. Линезолид - первый препарат нового класса антибактериальных средств оксазолидинонов. Качественная клиническая практика. 2002;(2):2-11.

For citation:


., . . Kachestvennaya klinicheskaya praktika. 2002;(2):2-11. (In Russ.)

Просмотров: 25


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2588-0519 (Print)
ISSN 2618-8473 (Online)